Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
V$438.91+2.32(+0.53%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$759.97-35.49(-4.46%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$289.81+2.51(+0.87%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.92-1.36(-2.33%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,460.30-35.84(-2.40%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.50-8.20(-2.52%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.70+0.53(+1.15%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.84+0.98(+0.96%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.31+4.31(+0.68%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.81+2.51(+0.87%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.55+5.04(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$196.95-3.34(-1.67%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.55+5.04(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.30-4.40(-2.56%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$557.50+1.70(+0.31%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ET

GRCE · NASDAQ

Grace Therapeutics, Inc.

$1.80 0.00 (0.00%)

Company overview

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is GTX-104, an intravenous infusion for the treatment of subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$29.3M
Employees
4
Headquarters
Princeton, NJ
Website
acastipharma.com
CEO
Prashant Kohli
Listed
February 7, 2012
P/E
-3.62
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$15.6M
EBITDA
-$15.6M
Net income
-$8.2M
EPS
-$0.50
Total assets
$68.5M
Total debt
$0.00
Earnings yield
-27.64%

Price chart

1.631.912.192.472.75
GRCE 1D NASDAQ O1.85H1.96L1.78C1.80-0.04 (-2.17%)Vol49.60K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026 GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Announces $10 Million Private Placement GlobeNewswire
GRCEGrace Therapeutics, Inc. Stock news Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened Defense World
GRCEGrace Therapeutics, Inc. Legal GRCE INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Grace Therapeutics, Inc. GlobeNewswire
GRCEGrace Therapeutics, Inc. Stock news Grace Therapeutics: Assessing The Path Forward For GTx-104 Seeking Alpha
GRCEGrace Therapeutics, Inc. Legal GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm Business Wire
GRCEGrace Therapeutics, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE GlobeNewswire
GRCEGrace Therapeutics, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE GuruFocus
GRCEGrace Therapeutics, Inc. Legal INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE PRNewsWire
GRCEGrace Therapeutics, Inc. Stock news Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug Benzinga
GRCEGrace Therapeutics, Inc. Stock news US FDA declines to approve Grace Therapeutics' drug for a type of stroke Reuters
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 GlobeNewswire
GRCEGrace Therapeutics, Inc. Stock news Short Interest in Grace Therapeutics, Inc. (NASDAQ:GRCE) Expands By 300.8% Defense World
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference GlobeNewswire
GRCEGrace Therapeutics, Inc. Press release Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update GlobeNewswire
GRCEGrace Therapeutics, Inc. Stock news Grace Therapeutics (GRCE) Expected to Announce Quarterly Earnings on Thursday Defense World
See more
FAQ

Questions about Grace Therapeutics, Inc.

What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is GTX-104, an intravenous infusion for the treatment of subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
What is GRCE's market cap?
Grace Therapeutics, Inc. (GRCE) is a listed stock with a live quote. The latest market cap on this page is $29.3M.
Where is Grace Therapeutics, Inc. headquartered?
Grace Therapeutics, Inc. is headquartered in Princeton, NJ.
How do I get GRCE news from the API?
Call GET /v1/news?tickers=GRCE. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does GRCE news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for GRCE, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the GRCE price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs